That is correct. We are working with different government stakeholders and look forward to meeting with them to further discuss the impact of these cuts. The reality is that we believe the work we're doing at BioCanRx is very much about bridging and filling a gap that exists in the ecosystem.
As I mentioned in my remarks, there is little to no funding for the kind of work that we do because it is required to meet the regulatory requirements of Health Canada so that we can get to a clinical trial. It's development work; it's very difficult funding to get.
Now, instead of focusing on what those later projects are going to be, we'll have to focus on attempting to find other partner dollars in order to bridge that gap. Again, we are very much focused on working with different government stakeholders to see a clear path through so that we can mitigate these cuts that are happening in the last year.
